Leqembi and Down Syndrome
The NTG has accumulated a selective library of publications and news regarding Leqembi (lecanemab) and Down syndrome.
On January 6, 2023 the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug designed to treat Alzheimer’s disease that was developed by the pharmaceutical firms Eisai and Biogen. Lecanemab, branded as Leqembi, was given full traditional approval on July 6, 2023 by the FDA to treat adults in the mild stage of Alzheimer’s dementia who also have “confirmed presence of amyloid beta pathology” in the brain. The presence of these amyloid beta plaques in the brain is one of the hallmarks of Alzheimer’s disease. An updated commentary on the FDA decision and subsequent release by CMS to have Medicare coverage for the drug is provided by Lumind IDSC. The NTG and Lumind IDSC are working cooperatively to ensure that state drug formularies do not include exclusions for access by adults with intellectual disability, including Down syndrome. A complementary effort is underway to include provisions for noting DS-AD and specialized DS-appropriate instruments on the CMS registry for Leqembi.
Relevant Publications

The Sun-Smart Collection
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.

Comfort X Design
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.

Transport In Style
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
